15.36

5.65% -0.92

After Hours: 15.66 0.30 +1.95%

Denali Therapeutics Inc (DNLI)

Overview News Price History Option Chain Financials Why DNLI Down? Discussions Forecast

Denali Therapeutics Inc stock is traded at $15.36, with a volume of 1.54M. It is down -5.65% in the last 24 hours and down -0.39% over the past month. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Previous Close:

$16.28

Open:

$15.98

24h Volume:

1.54M

Relative Volume:

0.80

Market Cap:

$2.25B

Revenue:

$340.81M

Net Income/Loss:

$-419.65M

P/E Ratio:

-5.3895

EPS:

-2.85

Net Cash Flow:

$-402.10M

1W Performance:

-5.24%

1M Performance:

-0.39%

6M Performance:

-6.57%

1Y Performance:

-43.22%

1-Day Range:

$15.00

$16.33

1-Week Range:

$15.00

$17.02

52-Week Range:

$10.57

$33.33

Denali Therapeutics Inc Stock (DNLI) Company Profile

Name

Denali Therapeutics Inc

Sector

Healthcare (1136)

Industry

Biotechnology (633)

Phone

(650) 866-8547

Address

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Employee

486

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

DNLI's Discussions on Twitter

Compare DNLI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNLI Denali Therapeutics Inc	15.36	2.38B	340.81M	-419.65M	-402.10M	-2.85
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Initiated	Deutsche Bank	Buy
Jan-07-25	Initiated	Robert W. Baird	Outperform
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Sep-06-23	Initiated	B. Riley Securities	Buy
Jan-30-23	Initiated	SVB Securities	Outperform
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy
Nov-02-22	Initiated	BofA Securities	Buy
Jun-23-22	Initiated	Berenberg	Buy
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform
Sep-01-21	Initiated	SMBC Nikko	Outperform
May-18-21	Initiated	UBS	Buy
Feb-26-21	Reiterated	H.C. Wainwright	Buy
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-11-20	Reiterated	H.C. Wainwright	Buy
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight
Aug-20-20	Reiterated	H.C. Wainwright	Buy
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform
Feb-28-20	Upgrade	Wedbush	Neutral → Outperform
Feb-24-20	Initiated	Jefferies	Buy
Feb-19-20	Initiated	Stifel	Hold
Jan-27-20	Upgrade	Goldman	Neutral → Buy
Sep-26-19	Initiated	Wedbush	Neutral
Sep-13-19	Initiated	Nomura	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-26-19	Initiated	H.C. Wainwright	Buy
Nov-15-18	Initiated	Cantor Fitzgerald	Overweight
Nov-12-18	Initiated	Janney	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Jan-02-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Initiated	Goldman	Neutral
Jan-02-18	Initiated	JP Morgan	Overweight
Jan-02-18	Initiated	Morgan Stanley	Overweight

View All

Denali Therapeutics Inc Stock (DNLI) Latest News

Nov 03, 2025

Can Denali Therapeutics Inc. (4DN) stock test all time highs2025 EndofYear Setup & Safe Capital Investment Plans - newser.com

Nov 03, 2025

Will Denali Therapeutics Inc. (4DN) stock outperform small cap peersMarket Performance Report & High Accuracy Investment Signals - newser.com

Nov 03, 2025

Why analysts remain bullish on Denali Therapeutics Inc. stockJuly 2025 Highlights & AI Forecast Swing Trade Picks - newser.com

Nov 03, 2025

Is Denali Therapeutics Inc. stock a top momentum play2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com

Nov 03, 2025

Why Denali Therapeutics Inc. stock is favored by pension fundsWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com

Nov 03, 2025

Will Denali Therapeutics Inc. stock outperform Nasdaq index2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com

Nov 03, 2025

Is Denali Therapeutics Inc. stock a dividend growth opportunityWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com

Nov 03, 2025

Comparing Denali Therapeutics Inc. in custom built stock radars2025 Short Interest & Fast Moving Trade Plans - newser.com

Nov 03, 2025

Is Denali Therapeutics Inc. stock supported by strong cash flows2025 AllTime Highs & High Accuracy Swing Trade Signals - newser.com

Nov 03, 2025

Nov 02, 2025

Is Denali Therapeutics Inc. stock ready for a breakoutAnalyst Downgrade & Risk Managed Investment Signals - newser.com

Nov 02, 2025

Is Denali Therapeutics Inc. stock a contrarian buy2025 Price Action Summary & Momentum Based Trading Ideas - newser.com

Nov 02, 2025

Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com

Nov 02, 2025

Will Denali Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com

Nov 02, 2025

Will Denali Therapeutics Inc. (4DN) stock enhance shareholder valueSell Signal & Weekly Return Optimization Alerts - newser.com

Nov 02, 2025

Pier Capital LLC Sells 20,708 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat

Nov 02, 2025